Electromyographic activity of the diaphragm during neostigmine or sugammadex-enhanced recovery after neuromuscular blockade with rocuronium. Issue 1 (January 2015)

• Record Type: Journal Article
• Authors: Schepens, Tom; Cammu, Guy; Saldien, Vera; De Neve, Nikolaas; Jorens, Philippe G.; Foubert, Luc; Vercauteren, Marcel
• Is Part Of: European journal of anaesthesiology. Volume 32:Issue 1(2015:Jan.)
• Publication Date: 2015-01
• Subjects: Anesthesiology -- Periodicals; Anesthesiology -- Periodicals; Anesthésiologie -- Périodiques; Anesthesiology; Periodicals; Electronic journals; 617.96
• DOI: 10.1097/EJA.0000000000000140
• Languages: English
• ISSNs: 0265-0215

Abstract

<abstract> <title> <x xml:space="preserve">Abstract</x> </title> <sec> <title>BACKGROUND</title> <p>The use of neuromuscular blocking agents has been associated with severe postoperative respiratory morbidity. Complications can be attributed to inadequate reversal, and reversal agents may themselves have adverse effects.</p> </sec> <sec> <title>OBJECTIVE</title> <p>To compare the electromyographic activity of the diaphragm (EMGdi) during recovery from neuromuscular blockade using neostigmine and sugammadex. The hypothesis was that there would be better neuromuscular coupling of the diaphragm when sugammadex was used.</p> </sec> <sec> <title>DESIGN</title> <p>A randomised, controlled, parallel-group, single-centre, double-blinded study.</p> </sec> <sec> <title>SETTING</title> <p>District general hospital in Belgium.</p> </sec> <sec> <title>PARTICIPANTS</title> <p>Twelve healthy male volunteers.</p> </sec> <sec> <title>INTERVENTIONS</title> <p>Individuals were anaesthetised with propofol and remifentanil. After rocuronium 0.6 mg kg<sup>−1</sup>, a transoesophageal electromyography (EMG) recorder was inserted. For reversal of neuromuscular blockade, volunteers received sugammadex 2 mg kg<sup>−1</sup> (<italic>n</italic> = 6) or neostigmine 70 μg kg<sup>−1</sup> (<italic>n</italic> = 6).</p> </sec> <sec> <title>MAIN OUTCOME MEASURES</title> <p>EMGdi, airway pressure and flow were continuously measured during weaning from the ventilator until tracheal extubation. Arterial blood gas samples were obtained for PaO<sub>2</sub> and PaCO<sub>2</sub> analysis at the first spontaneous breathing attempt and after tracheal extubation.</p> </sec> <sec> <title>RESULTS</title> <p>During weaning, 560 breaths were retained for analysis. The median (95% CI) peak EMGdi was 1.1 (0.9 to 1.5) μV in the neostigmine group and 1.6 (1.3 to 1.9) μV in the sugammadex group (<italic>P</italic> < 0.001). Individuals in the neostigmine group had 125 of 228 (55%) breaths with associated EMGdi at least 1 μV vs. 220 of 332 (66%) breaths in the sugammadex group (<italic>P</italic> = 0.008). The median (95% CI) tidal volume was 287 (256 to 335) ml after neostigmine and 359 (313 to 398) ml after sugammadex (<italic>P</italic> = 0.013). The median (95% CI) PaO<sub>2</sub> immediately after extubation was 30.5 (22.8 to 37.1) kPa after sugammadex vs. 20.7 (12.9 to 27.5) kPa after neostigmine (<italic>P</italic> = 0.03).</p> </sec> <sec> <title>CONCLUSION</title> <p>EMGdi, tidal volume and PaO<sub>2</sub> following tracheal extubation were increased after sugammadex compared with neostigmine, reflecting diaphragm-driven inspiration after sugammadex administration. Sugammadex may free more diaphragmatic acetylcholine receptors than neostigmine, which has an indirect effect.</p> </sec> <sec> <title>TRIAL REGISTRATION</title> <p>EudraCT ref: 2013-002078-30.</p> </sec> </abstract>